65,437 trials
Diabetes Mellitus, Type 1
Primary: Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period — -0.14; -0.19 percentage of hemoglobin A1C — p=0.2878
Healthy Volunteers
Primary: Amount of Testosterone on T-shirts — 7603 micrograms (µg)
Edentulism
Primary: Effectiveness - Treatment Difference in Mean Change in Crestal Bone Level — 13; 55 Percentage of implants
Hypertension · Heart Failure
Primary: Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes — 15.0; NA Minutes
High Risk Stage III Melanoma
Primary: Recurrence Free Survival (RFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population — 26.09; 17.05 months — p=0.0013
Schizophrenia
Primary: Positive and Negative Syndrome Scale (PANSS) — -.21; -.22 units on a scale
Hematologic Diseases · Hematologic Malignancies
Primary: Numbers of Participants With Disease-free Survival. — 10 participants
Alpha 1-Antitrypsin Deficiency
Primary: Treatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion. — 38; 26; 17; 5…
Overactive Bladder
Primary: Change From Baseline in Maximum Cystometric Capacity at 4 Hours Post Dose 7 on Tolterodine 4 mg and Placebo — 1.15; 0.94 Percentage change — p=0.008
Healthy
Primary: AUC0-72 of Linagliptin — 317.0; 319.2; 309.6; 304.9 nmol*h/L
Persistent Atrial Fibrillation
Primary: Time From Randomization to First Documented AF Recurrence. — 51.0; NA; 117.0; 58.0 Days
Migraine
Primary: Percentage of Participants With At Least One Triptan-Related Adverse Experience (AE) — 5.0; 11.2 Percentage of Participants — p=<0.001
Compliance Behavior
Primary: Number of Participants With a Decrease of 2 Points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) Analysis is Per Protocol — 10; 13 participants
Neoplasms, Breast
Primary: Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])…
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored (ADHD-RS-IV-PV:IR) Total Score…